February 2010 Volume 7 Number 2
Visit Nature Reviews Gastroenterology & Hepatology online to browse
the journal.
Now available at
http://links.ealert.nature.com/ctt?kn=71&m=34608396&r=MTc2OTYyOTQ2MwS2&b=2&j=NjY5MTMxMDkS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access
to Nature Reviews Gastroenterology & Hepatology online. To purchase a
subscription, please visit:
http://links.ealert.nature.com/ctt?kn=32&m=34608396&r=MTc2OTYyOTQ2MwS2&b=2&j=NjY5MTMxMDkS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=67&m=34608396&r=MTc2OTYyOTQ2MwS2&b=2&j=NjY5MTMxMDkS1&mt=1&rt=0
*********************************************************************
Nature Reviews Gastroenterology & Hepatology Impact Factor: 4.550*
(*Journal Citation Reports, Thomson, 2008)
*********************************************************************
=========================== ADVERTISEMENT ===========================
Focus Issue: Biologic therapies for IBD
In the February issue of Nature Reviews Gastroenterology & Hepatology,
leaders in the field provide an update on the current status of biologic
therapies for IBD and set the stage for developments in the near and
distant future. Encompassing discussion of the potential for disease
modification, therapeutic rationale and requisite evidence, safety,
pharmacoeconomics and future targets, this Focus issue provides a
valuable and cutting-edge resource for clinicians and researchers.
Visit http://links.ealert.nature.com/ctt?kn=59&m=34608396&r=MTc2OTYyOTQ2MwS2&b=2&j=NjY5MTMxMDkS1&mt=1&rt=0
to access these reviews.
=====================================================================
----------------------
EDITORIAL
----------------------
Focus on: The future of biologic therapy for IBD
The expanding role of biologic therapy for IBD
Stephen B. Hanauer
p63 | doi:10.1038/nrgastro.2009.238
http://links.ealert.nature.com/ctt?kn=43&m=34608396&r=MTc2OTYyOTQ2MwS2&b=2&j=NjY5MTMxMDkS1&mt=1&rt=0
----------------------
RESEARCH HIGHLIGHTS
----------------------
IBD: High dietary intake of linoleic acid more than doubles the risk of
ulcerative colitis
p65 | doi:10.1038/nrgastro.2009.224
http://links.ealert.nature.com/ctt?kn=53&m=34608396&r=MTc2OTYyOTQ2MwS2&b=2&j=NjY5MTMxMDkS1&mt=1&rt=0
H. Hepaticus and biliary disease
p66 | doi:10.1038/nrgastro.2009.229
http://links.ealert.nature.com/ctt?kn=51&m=34608396&r=MTc2OTYyOTQ2MwS2&b=2&j=NjY5MTMxMDkS1&mt=1&rt=0
Pancreas: New antibody may aid diagnosis of autoimmune pancreatitis
p66 | doi:10.1038/nrgastro.2009.230
http://links.ealert.nature.com/ctt?kn=49&m=34608396&r=MTc2OTYyOTQ2MwS2&b=2&j=NjY5MTMxMDkS1&mt=1&rt=0
Obesity: Lifestyle counseling ineffective in tackling childhood obesity
p67 | doi:10.1038/nrgastro.2009.226
http://links.ealert.nature.com/ctt?kn=46&m=34608396&r=MTc2OTYyOTQ2MwS2&b=2&j=NjY5MTMxMDkS1&mt=1&rt=0
IBD: Thiopurines increase risk of lymphoproliferative disorders in
patients with IBD
p67 | doi:10.1038/nrgastro.2009.227
http://links.ealert.nature.com/ctt?kn=24&m=34608396&r=MTc2OTYyOTQ2MwS2&b=2&j=NjY5MTMxMDkS1&mt=1&rt=0
Obesity: Liraglutide induces weight loss
p68 | doi:10.1038/nrgastro.2009.228
http://links.ealert.nature.com/ctt?kn=27&m=34608396&r=MTc2OTYyOTQ2MwS2&b=2&j=NjY5MTMxMDkS1&mt=1&rt=0
Gallstones: Statin use is associated with a reduced risk of cholesterol
gallstones
p68 | doi:10.1038/nrgastro.2009.231
http://links.ealert.nature.com/ctt?kn=17&m=34608396&r=MTc2OTYyOTQ2MwS2&b=2&j=NjY5MTMxMDkS1&mt=1&rt=0
Hepatic artery thrombosis
p69 | doi:10.1038/nrgastro.2009.223
http://links.ealert.nature.com/ctt?kn=22&m=34608396&r=MTc2OTYyOTQ2MwS2&b=2&j=NjY5MTMxMDkS1&mt=1&rt=0
IBD: Is treatment with a third anti-TNF agent a safe and effective option
in patients with Crohn's disease?
p70 | doi:10.1038/nrgastro.2009.225
http://links.ealert.nature.com/ctt?kn=3&m=34608396&r=MTc2OTYyOTQ2MwS2&b=2&j=NjY5MTMxMDkS1&mt=1&rt=0
IBD: Intensive GMA is more efficacious than weekly GMA for the treatment
of ulcerative colitis
p70 | doi:10.1038/nrgastro.2009.239
http://links.ealert.nature.com/ctt?kn=41&m=34608396&r=MTc2OTYyOTQ2MwS2&b=2&j=NjY5MTMxMDkS1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
GERD: Are functional heartburn and functional dyspepsia one disorder?
Tiberiu Hershcovici and Ronnie Fass
p71 | doi:10.1038/nrgastro.2009.233
The characteristics of functional heartburn remain poorly understood.
Savarino et al. have now demonstrated that functional heartburn has more
in common with functional dyspepsia than with nonerosive reflux disease.
This study suggests that there is substantial overlap between functional
heartburn and functional dyspepsia, and possibly that these two disorders
may actually be one functional esophagogastric disorder.
http://links.ealert.nature.com/ctt?kn=39&m=34608396&r=MTc2OTYyOTQ2MwS2&b=2&j=NjY5MTMxMDkS1&mt=1&rt=0
Pancreas: Is there still a role for total pancreatectomy?
Marcus Bahra and Peter Neuhaus
p72 | doi:10.1038/nrgastro.2009.234
The role of total pancreatectomy for pancreatic adenocarcinoma is
controversial. Concerns have been raised about increased morbidity and
mortality, and poorer long-term outcomes associated with total pancreatectomy
compared with pancreaticoduodenectomy. Reddy and colleagues recently reported
data that support the use of total pancreatectomy, when appropriate, in
clinical practice.
http://links.ealert.nature.com/ctt?kn=37&m=34608396&r=MTc2OTYyOTQ2MwS2&b=2&j=NjY5MTMxMDkS1&mt=1&rt=0
Primary sclerosing cholangitis: What is the role of ursodeoxycholic acid
in therapy for PSC?
Roger W. Chapman
p74 | doi:10.1038/nrgastro.2009.235
Ursodeoxycholic acid (UDCA) is widely used for the treatment of chronic
cholestatic liver diseases. However, a recent randomized, controlled trial
has surprisingly shown that the use of high-dose UDCA in patients with
primary sclerosing cholangitis (PSC) may be harmful; adverse events, such
as death and liver transplantation, were significantly higher in patients
who received UDCA compared with placebo.
http://links.ealert.nature.com/ctt?kn=35&m=34608396&r=MTc2OTYyOTQ2MwS2&b=2&j=NjY5MTMxMDkS1&mt=1&rt=0
Liver: Management of non-acetaminophen-induced ALF
Stephen M. Riordan and Roger Williams
p75 | doi:10.1038/nrgastro.2009.236
The first prospective, double-blind, randomized controlled study of
acetylcysteine for the treatment of patients with non-acetaminophen-induced
acute liver failure supports its use in patients in the early stages of
liver failure. Emergency liver transplantation still has a fundamental
role in the management of patients with the most severe form of this
syndrome.
http://links.ealert.nature.com/ctt?kn=31&m=34608396&r=MTc2OTYyOTQ2MwS2&b=2&j=NjY5MTMxMDkS1&mt=1&rt=0
Diverticular disease: What is the best long-term treatment?
Antonio Tursi
p77 | doi:10.1038/nrgastro.2009.237
Some patients who have diverticular disease develop complications or
recurrent symptoms and medical therapy may be necessary. Findings from
recent studies suggest that rifaximin, a poorly absorbed antibiotic,
should be recommended for long-term treatment of diverticular disease;
however, the anti-inflammatory drug mesalazine seems to be more promising
in the long term.
http://links.ealert.nature.com/ctt?kn=68&m=34608396&r=MTc2OTYyOTQ2MwS2&b=2&j=NjY5MTMxMDkS1&mt=1&rt=0
=====================================================================
Focus on: The future of biologic therapy for IBD
----------------------
REVIEWS
----------------------
The potential for disease modification in Crohn's disease
Gert Van Assche, Severine Vermeire and Paul Rutgeerts
p79 | doi:10.1038/nrgastro.2009.220
Treatment of patients with Crohn's disease to delay the natural evolution
of the disease and avoid the development of complicated disease as well
as the need for hospitalization and surgery is desirable. Gert Van Assche
and colleagues discuss the disease-modifying potential of immunosuppressive
and anti-tumor necrosis factor therapies, especially when given as early,
aggressive therapy.
Abstract: http://links.ealert.nature.com/ctt?kn=83&m=34608396&r=MTc2OTYyOTQ2MwS2&b=2&j=NjY5MTMxMDkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=60&m=34608396&r=MTc2OTYyOTQ2MwS2&b=2&j=NjY5MTMxMDkS1&mt=1&rt=0
Top-down therapy for IBD: rationale and requisite evidence
Geert R. D'Haens
p86 | doi:10.1038/nrgastro.2009.222
Early treatment of Crohn's disease with immunomodulators and anti-TNF
agents is associated with better clinical outcomes than standard therapy,
but these drugs may have serious adverse effects and are not suitable
for all patients. The author reviews current clinical evidence and
proposes a strategy for adequate selection of patients for top-down
therapy of IBD.
Abstract: http://links.ealert.nature.com/ctt?kn=82&m=34608396&r=MTc2OTYyOTQ2MwS2&b=2&j=NjY5MTMxMDkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=61&m=34608396&r=MTc2OTYyOTQ2MwS2&b=2&j=NjY5MTMxMDkS1&mt=1&rt=0
Optimizing the safety of biologic therapy for IBD
Shanika de Silva, Shane Devlin and Remo Panaccione
p93 | doi:10.1038/nrgastro.2009.221
Despite the widespread use of biologic therapy for IBD, safety concerns
still exist. To realize the full potential of these therapies it is
important to select appropriate patients for therapy and to optimize the
delivery of these agents, thus maximizing their effectiveness. At the
same time it is important to adopt strategies before and during treatment
that minimize the occurrence of adverse effects. This Review outlines the
adverse events associated with biologic therapies, and gives
recommendations on how to reduce the risk of these events.
Abstract: http://links.ealert.nature.com/ctt?kn=15&m=34608396&r=MTc2OTYyOTQ2MwS2&b=2&j=NjY5MTMxMDkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=45&m=34608396&r=MTc2OTYyOTQ2MwS2&b=2&j=NjY5MTMxMDkS1&mt=1&rt=0
The pharmacoeconomics of biologic therapy for IBD
Russell D. Cohen
p103 | doi:10.1038/nrgastro.2009.232
IBD is associated with a young age at onset and normal life expectancy,
which results in a lifetime accrual of disease-related costs. This Review
discusses the economic impact of biologic therapy on direct costs of IBD,
such as hospitalizations and surgeries, and indirect costs, such as those
related to disability and loss of productivity.
Abstract: http://links.ealert.nature.com/ctt?kn=21&m=34608396&r=MTc2OTYyOTQ2MwS2&b=2&j=NjY5MTMxMDkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=81&m=34608396&r=MTc2OTYyOTQ2MwS2&b=2&j=NjY5MTMxMDkS1&mt=1&rt=0
Future biologic targets for IBD: potentials and pitfalls
Gil Y. Melmed and Stephan R. Targan
p110 | doi:10.1038/nrgastro.2009.218
IBD treatment has evolved towards biologic therapy, which seeks to target
specific immune and biochemical abnormalities at the molecular and cellular
level. Improved understanding of the pathogenesis of IBD has suggested
future drug biologic targets, which are currently being investigated. This
Review article discusses the potentials and pitfalls of biologic therapy
for IBD as this field advances at a rapid pace.
Abstract: http://links.ealert.nature.com/ctt?kn=18&m=34608396&r=MTc2OTYyOTQ2MwS2&b=2&j=NjY5MTMxMDkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=75&m=34608396&r=MTc2OTYyOTQ2MwS2&b=2&j=NjY5MTMxMDkS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
nature.com Open Innovation Pavilion
Solve for a cause!
Nature Publishing Group is proud to sponsor a Challenge by the Drugs
for Neglected Diseases initiative. Your ideas to solve this Challenge
can help change the lives of those suffering from African sleeping
sickness, Chagas disease or Leishmaniasis.
Visit http://links.ealert.nature.com/ctt?kn=80&m=34608396&r=MTc2OTYyOTQ2MwS2&b=2&j=NjY5MTMxMDkS1&mt=1&rt=0
to read more about this Challenge and how you can help.
=====================================================================
You have been sent this Table of Contents Alert because you have opted
in to receive it. You can change or discontinue your e-mail alerts at
any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=66&m=34608396&r=MTc2OTYyOTQ2MwS2&b=2&j=NjY5MTMxMDkS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2010 Nature Publishing Group
=====================================================================
